The purpose of this study is to analyze the efficacy of type II and III SMA patients treated with nusinersen, grouping according to clinical efficacy, detecting the expression of SMN protein in patients with different effects. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.